2nd International Conference on Retroviruses and Novel Drugs
Cape Town, South Africa
Scientific Director, CRPH, University of Health Sciences-Libreville, Africa
Title: ImmunorexTM at the Final Stage of Development for Commercialization as a Model of Academic CRO / Industrial Collaboration
Biography: Donatien Mavoungou
ImmunorexTM has a history of 40 years of studies on Monoamine oxidase (MOA) and DHEA in Cardiovascular diseases (High Blood Pressure) and in infection including HVI-1 known today to increase cardiovascular and cerebrovascular diseases via oxidative stress leading to inflammation and neuro-virulence. ImmunorexTM is an immune-regulator with the capacity to block HIV-1 replication, to restore Th1 and Th2 equilibrium improving antibodies against HIV-Tat. It can also treat and prevent co-infections such as Tuberculosis, Malaria, Hepatitis B and C. The drug is an inhibitor of NADPH, the co-factor of G6PD resulting in the restoration of endothelial function producing Nitric oxide (NO) able to suppress neuro-inflammation and to influence Na/K Pump for blood pressure regulation. We want to present here ImmunorexTM at its final stage of development for commercialization as a model of collaboration between Academic CRO and Industry for young scientists particularly in developing countries.